Skip to content

Epidemiology and burden

TL;DR — There is no single prevalence of IBS; there is a prevalence per criteria set. Pooling only population studies with uniform methodology, Rome III gives 9.2% (95% CI 7.6–10.8) and Rome IV gives 3.8% (3.1–4.5) — a 2.4-fold gap produced by the definition, not by the population (Oka 2020, PMID 32702295). The same discontinuity appears within single surveys: 10.1% vs 4.1% in the Rome Foundation internet arm (Sperber 2021, PMID 32294476) and 9.0% vs 4.6% in a US/Canada/UK survey (Palsson 2020, PMID 31917991). Rome V, applied to 28,771 adults in 15 countries in 2026, returned IBS at 8.5% — closer to the Rome III era than to Rome IV (Sperber 2026, PMID 42613194). Women are affected roughly 1.5-fold more often (OR 1.46, 1.33–1.59; Oka 2020, PMID 32702295), true prevalence varies several-fold between countries even under identical methods, and prevalence declines with age (OR 0.75, 0.62–0.92 for >50 vs <50; Lovell 2012, PMID 22426087). The economic burden is dominated by indirect costs: in a 33-study cost-of-illness review spanning 14 countries, direct costs ranged from US$193/patient/year (Korea) to US$31,113 (US, IBS-C), and in Sweden indirect costs for IBS-C exceeded direct costs roughly nine-fold (US$17,112 vs US$1,943) (Neo 2026, PMID 42538760). The biggest unresolved question is whether between-country variation is biological, cultural, or an artefact of the questionnaire's translation.

Prevalence depends on the rule, then on the country

Source Population Criteria Prevalence
Oka 2020, PMID 32702295 53 studies, 38 countries, 395,385 participants Rome III 9.2% (95% CI 7.6–10.8), I²=99.7%
Oka 2020, PMID 32702295 6 studies, 34 countries, 82,476 participants Rome IV 3.8% (3.1–4.5), I²=96.6%
Sperber 2021, PMID 32294476 73,076 adults, 33 countries (internet arm) Rome IV vs Rome III 4.1% vs 10.1%
Sperber 2021, PMID 32294476 Household-interview arm Rome IV vs Rome III 1.5% vs 3.5%
Palsson 2020, PMID 31917991 5,931 adults, USA/Canada/UK Rome IV vs Rome III 4.4–4.8% by country vs 9.0% overall
Almario 2023, PMID 37595647 88,607 US adults, online, May–June 2020 Rome IV 6.1% (5,414 cases)
Sperber 2026, PMID 42613194 28,771 adults, 15 countries Rome V 8.5%
Lovell 2012, PMID 22426087 80 populations, 260,960 subjects mixed (Manning/Rome I–III) 11.2% (9.8–12.8); range across countries 1.1–45.0%
Arif 2025, PMID 40359286 96 studies, 52 countries Rome III or IV 14.1%
Ballena-Caicedo 2025, PMID 41488823 43 studies, 188,885 participants Rome III / Rome IV 13.21% (10.70–15.94) / 17.14% (12.00–22.99); 11.19% / 13.28% restricted to probabilistic sampling
Takeoka 2023, PMID 37019867 3,910 urban adults, Japan/China/South Korea Rome III 12.6% (11.6–13.7), differing significantly between the three countries
Krogsgaard 2017, PMID 27865035 5,986 Danes aged 18–50, web panel Rome III 15.4%; 3-year incidence 10.3%

Two of these estimates disagree with the rest in a way that matters. Ballena-Caicedo 2025 (PMID 41488823) reports Rome IV prevalence higher than Rome III (17.14% vs 13.21%), the opposite direction to Oka 2020, Sperber 2021 and Palsson 2020, and attributes it to "a more precise definition of abdominal pain." Arif 2025 (PMID 40359286) reports 14.1% overall. Neither used the restriction that produced the low Rome IV figures — Oka's inclusion criteria demanded uniform population-based methodology, and its Rome IV pool was only six studies. These estimates are shown side by side because averaging them would conceal the methodological disagreement that generates them. Oka's own interpretation is that the more restrictive Rome IV criteria "might be less suitable than Rome III for population-based epidemiological surveys" (PMID 32702295).

Country variation survives criteria harmonisation. Oka 2020 found prevalence "varies substantially between countries, and this variability persisted even when the same diagnostic criteria were applied and identical methodology was used" (PMID 32702295); Lovell 2012 recorded a 1.1%–45.0% range across countries (PMID 22426087); Takeoka 2023 found significant differences between three East Asian capitals surveyed with one instrument (PMID 37019867). Whether that residual variation is real, cultural, or a translation artefact is unresolved — Black and Ford note the Rome criteria were "developed with reference to research conducted largely in Western populations" and may be "limited in their applicability to other countries and cultures" (Black 2020, PMID 32296140).

Subtype distribution

Source Criteria IBS-C IBS-D IBS-M IBS-U
Oka 2020, PMID 32702295 Rome III — — 33.8% (most common) —
Oka 2020, PMID 32702295 Rome IV — 31.5% (most common) — —
Almario 2023, PMID 37595647 Rome IV (US, n=5,414) 33.6% 28.1% 33.9% 4.4%
Arif 2025, PMID 40359286 Rome III + IV pooled 26.1% 26.5% 31.4% 8.3%
Arif 2025, PMID 40359286 by criteria IBS-C 34.2% under Rome IV IBS-D 26.2% under Rome III — —
Shin 2023, PMID 35964894 Rome IV, US veterans (n=244) 16.8% 47.5% 33.6% —

The subtype mix therefore also moves with the criteria set: the modal subtype is IBS-M under Rome III and IBS-D under Rome IV in the same meta-analysis (Oka 2020, PMID 32702295). This is not a stable trait of individuals either — see diagnosis-and-rome-criteria for the 12-month stability data (κ 0.60 for stool-form subtyping; Khasawneh 2026, PMID 41447016).

Sex, age and demography

  • Sex. Pooled OR for women 1.46 (1.33–1.59), prevalence 12.0% vs 8.6% (Oka 2020, PMID 32702295); an earlier and broader pool gave OR 1.67 (1.53–1.82) (Lovell 2012, PMID 22426087); the pooled figure across 96 studies was OR 1.49 (Arif 2025, PMID 40359286). In the Million Veteran Program (546,246 veterans; 9.0% women), IBS prevalence was 13.8% in women versus 4.2% in men, highest in White women at 14.7% (Gasperi 2026, PMID 41489281).
  • Age. Prevalence is lower over 50 (OR 0.75, 0.62–0.92) (Lovell 2012, PMID 22426087); DGBI prevalence "decreased with increasing age" in both Rome IV and Rome V global surveys (Sperber 2026, PMID 42613194).
  • Race/ethnicity. In the 88,607-person US survey, racial and ethnic minorities had lower odds of Rome IV IBS than non-Hispanic Whites (Almario 2023, PMID 37595647) — a finding that could reflect true difference, differential symptom reporting, or survey access, and which has not been mechanistically explained.
  • Psychological covariates. Pooled ORs for stress 2.47, anxiety 2.93, depression 2.24; no significant association with smoking, alcohol or education (Arif 2025, PMID 40359286). Direction of causation is addressed on brain-gut-axis-and-visceral-hypersensitivity.

Incidence, persistence and remission

IBS is a fluctuating condition whose prevalence is stable because incidence and remission roughly cancel. Community incidence is approximately 67 per 1,000 person-years, reported resolution across population studies ranges 17–55%, and in a clinical-trial cohort only one in four patients retained their baseline subtype throughout (Yadav 2021, PMID 34927758). In the Danish 3-year cohort, incidence was 10.3% over the period and three-fold higher in people with non-specific GI symptoms at baseline than in asymptomatic people; 69% of those with IBS symptoms at both 2010 and 2011 still had them in 2013, versus 20% of those who had become asymptomatic in 2011 (Krogsgaard 2017, PMID 27865035). One large driver of new-onset disease — acute enteric infection — has its own page (post-infectious-ibs).

Health-care seeking and utilisation

  • 68.2–73.2% of US Rome IV cases had ever sought care for IBS symptoms; 53.8–58.9% had done so in the past 12 months (Almario 2023, PMID 37595647).
  • Among US veterans, IBS carried adjusted ORs of 2.08 for multiple doctor visits and 1.78 for hospitalisation, alongside anxiety OR 3.47, depression OR 2.88 and PTSD OR 3.09 (Shin 2023, PMID 35964894).
  • Endoscopy is a major cost driver but a low-yield one at first diagnosis: see differential-diagnosis-and-exclusion (Staller 2021, PMID 34420846).
  • People in the highest-psychological-burden latent class incurred >£1,000/person/year in IBS-related costs in a UK community cohort (Black 2024, PMID 36858142).

Economic burden

Source Scope Direct cost Indirect cost Note
Neo 2026, PMID 42538760 33 studies, 14 countries, 1992–2022; inflation-adjusted to 2024 US$ US$193 (Korea) to US$31,113 (US, IBS-C) per patient/year Frequently the dominant share where a societal perspective was taken; Sweden IBS-C US$17,112 indirect vs US$1,943 direct IBS-C had the highest subtype-specific costs; treatment failure predicted higher spend
Flacco 2019, PMID 31002149 24 European studies, universal-coverage systems €1,837/year (95% CI 1,480–2,195), range €1,183–3,358 by payer type €2,314/year (1,811–2,817) Total €2,889/year (2,318–3,460); ~€6–8 bn/year attributed to Italy
Buono 2017, PMID 28345443 19,653 US commercially insured IBS-D patients, 1:1 matched controls, 2013 All-cause US$13,038/year; GI-related US$3,817; symptom-related US$1,693 not assessed Adjusted incremental all-cause cost US$2,268/year (US$9,436 vs US$7,169), 78% medical / 22% pharmacy
Tack 2019, PMID 31064345 Moderate–severe IBS-C, six European countries (IBIS-C) see source see source Prospective multi-country burden study
Nellesen 2013, PMID 24156644 Systematic review, IBS and chronic constipation see source see source Notes 14% (IBS) and 20% (CC) US prevalence figures from the pre-Rome-IV era

The consistent finding across these is directional rather than numeric: studies that count only direct health-care spending underestimate the burden, because absenteeism, presenteeism and lost productivity dominate when a societal perspective is used (Neo 2026, PMID 42538760; Flacco 2019, PMID 31002149). The absolute numbers are not comparable across studies — different criteria eras, different health systems, different cost definitions — and are shown here unaveraged for that reason.

Quality-of-life burden

  • People with any Rome IV functional bowel disorder had significantly reduced SF-8 quality of life and more GI consultations than other respondents in a 5,931-person survey (Palsson 2020, PMID 31917991).
  • Globally, DGBI were associated with lower quality of life and more frequent doctor visits (Sperber 2021, PMID 32294476).
  • Latent-class analysis shows the burden is concentrated: the four highest-psychological-burden clusters carried most of the impairment in quality of life, earnings, work productivity and social function (Black 2024, PMID 36858142; reproduced globally in Black 2025, PMID 38876193). Detail on quality-of-life-and-stigma.

What the epidemiology does not establish

  • Mortality. A 2025 NIH–AARP cohort linked 5,030 people with claims-identified IBS among 132,697 participants to the National Death Index. Adjusted all-cause mortality was lower in IBS at >2–5 years (HR 0.75, 95% CI 0.64–0.88) and the inverse association attenuated by >17 years (HR 0.92, 0.87–0.98); the authors emphasised time-varying confounding by health advocacy and healthcare access rather than a protective effect (Gutiérrez-Torres 2025, PMID 41518229). This does not support excess mortality, but it replaces the previous claim that population mortality data were absent.
  • True international variation. Between-country differences survive methodological harmonisation but the causal contribution of diet, infection burden, health-system access, language and stigma has not been partitioned (Black 2020, PMID 32296140; Oka 2020, PMID 32702295).
  • Whether prevalence is rising. Meta-regression showed "a trend toward increased prevalence in recent years" (Ballena-Caicedo 2025, PMID 41488823), while the Rome V and Rome IV global surveys returned near-identical aggregate DGBI prevalence six years apart (40.9% vs 40.5%; Sperber 2026, PMID 42613194). The US 6.1% figure was collected in May–June 2020 and its authors explicitly flag possible COVID-19 pandemic inflation (Almario 2023, PMID 37595647).

Open questions

  • Which prevalence figure should a health system plan against, when Rome III and Rome IV differ 2.4-fold in the same meta-analysis (Oka 2020, PMID 32702295) and Rome V returns 8.5% (Sperber 2026, PMID 42613194)?
  • Is the residual between-country variation real? A targeted PubMed search on 2026-09-02 retrieved no study decomposing it into biological, dietary, health-system and translation components (Black 2020, PMID 32296140).
  • Why is Rome IV prevalence higher than Rome III in one 2025 meta-analysis (PMID 41488823) and roughly half of it in three others (PMID 32702295, 32294476, 31917991)? This is a direct, unresolved contradiction in the literature.
  • Does the lower measured prevalence in US racial and ethnic minorities (Almario 2023, PMID 37595647) reflect biology, reporting, or access?
  • What fraction of IBS's societal cost is recoverable by treatment? Cost-of-illness studies show treatment failure predicts higher spend (Neo 2026, PMID 42538760), and ACTIB and exposure-based CBT have published societal-perspective economic analyses; a targeted PubMed search on 2026-09-02 retrieved no trial using total societal cost as its primary clinical endpoint.
  • Is there any excess mortality? Population-based mortality follow-up in criteria-defined IBS was not retrievable in this session's searches.

References

  1. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-917. PMID 32702295
  2. Sperber AD, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. PMID 32294476
  3. Sperber AD, et al. Rome V global epidemiology and validation survey. Gut. 2026 Aug 18 (online ahead of print). PMID 42613194
  4. Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262-1273.e3. PMID 31917991
  5. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.e4. PMID 22426087
  6. Almario CV, Sharabi E, Chey WD, Lauzon M, Higgins CS, Spiegel BMR. Prevalence and Burden of Illness of Rome IV Irritable Bowel Syndrome in the United States. Gastroenterology. 2023;165(6):1475-1487. PMID 37595647
  7. Arif TB, et al. Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis. Eur J Gastroenterol Hepatol. 2025;37(12):1314-1325. PMID 40359286
  8. Ballena-Caicedo J, Valladolid-Sandoval LAM, Zuzunaga-Montoya FE, Vera-Ponce VJ. Global Prevalence of Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Gastroenterology Res. 2025;18(6):308-321. PMID 41488823
  9. Takeoka A, et al. Prevalence of Irritable Bowel Syndrome in Japan, China, and South Korea: An International Cross-sectional Study. J Neurogastroenterol Motil. 2023;29(2):229-237. PMID 37019867
  10. Krogsgaard LR, Engsbro AL, Jones MP, Bytzer P. The epidemiology of irritable bowel syndrome: Symptom development over a 3-year period in Denmark. Neurogastroenterol Motil. 2017;29(4). PMID 27865035
  11. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473-486. PMID 32296140
  12. Gasperi M, Gerstenberger A, Naliboff B, Afari N. Exploring Sex Differences in Irritable Bowel Syndrome Prevalence, Environmental Risk, and Comorbidities: A Population-Based Cohort Study of Veterans. Clin Transl Gastroenterol. 2026;17(3):e00967. PMID 41489281
  13. Shin A, Xu H, Imperiale TF. The Prevalence, Humanistic Burden, and Health Care Impact of Irritable Bowel Syndrome Among United States Veterans. Clin Gastroenterol Hepatol. 2023;21(4):1061-1069.e1. PMID 35964894
  14. Yadav YS, Eslick GD, Talley NJ. Review article: irritable bowel syndrome: natural history, bowel habit stability and overlap with other gastrointestinal disorders. Aliment Pharmacol Ther. 2021;54 Suppl 1:S24-S32. PMID 34927758
  15. Neo KML, et al. Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review. J Gastroenterol Hepatol. 2026;41(9):2557-2570. PMID 42538760
  16. Flacco ME, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986-3000. PMID 31002149
  17. Buono JL, Mathur K, Averitt AJ, Andrae DA. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population. J Manag Care Spec Pharm. 2017;23(4):453-460. PMID 28345443
  18. Tack J, et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19(1):69. PMID 31064345
  19. Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013;19(9):755-64. PMID 24156644
  20. Black CJ, Ng CE, Goodoory VC, Ford AC. Novel Symptom Subgroups in Individuals With Irritable Bowel Syndrome Predict Disease Impact and Burden. Clin Gastroenterol Hepatol. 2024;22(2):386-396.e10. PMID 36858142
  21. Black CJ, et al. Novel Irritable Bowel Syndrome Subgroups Are Reproducible in the Global Adult Population. Clin Gastroenterol Hepatol. 2025;23(6):1039-1048.e7. PMID 38876193
  22. Khasawneh M, Goodoory VC, Ng CE, Ford AC, Black CJ. Stability of Classification Systems for Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2026;63(8):1132-1139. PMID 41447016
  23. Staller K, et al. Diagnostic yield of endoscopy in irritable bowel syndrome: A nationwide prevalence study 1987-2016. Eur J Intern Med. 2021;94:85-92. PMID 34420846
  24. Gutiérrez-Torres DS, et al. The Time-Dependent Association Between Irritable Bowel Syndrome and All-Cause and Cause-Specific Mortality in the NIH-AARP Cohort Study. Am J Gastroenterol. 2025; advance online publication. PMID 41518229